ESR1 and breast carcinoma: First, we studied the expression of hnRNPK using estradiol (E2) and ERα antagonist ICI 182,780 treatment using the ERα-positive breast carcinoma cell line MCF-7 to explore the potential association between hnRNPK and the ER-mediated signaling pathway.